- Home
- MKLY vs IKT Comparison
MKLY vs IKT Comparison
Compare MKLY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKLY | IKT |
|---|---|---|
| Founded | 2025 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.6M | 201.3M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MKLY | IKT |
|---|---|---|
| Price | $10.01 | $1.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 77.1K | ★ 647.5K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $1.33 |
| 52 Week High | $10.05 | $3.32 |
Technical Indicators
Market Signals| Indicator | MKLY | IKT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.51 |
| Support Level | N/A | $1.63 |
| Resistance Level | N/A | $1.73 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 8.50 |
Price Performance
Historical ComparisonAbout MKLY McKinley Acquisition Corporation Class A Ordinary Shares
McKinley Acquisition Corp is a blank check company.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.